EP0431905A1 - Method for purifying phage DNA - Google Patents

Method for purifying phage DNA Download PDF

Info

Publication number
EP0431905A1
EP0431905A1 EP90313173A EP90313173A EP0431905A1 EP 0431905 A1 EP0431905 A1 EP 0431905A1 EP 90313173 A EP90313173 A EP 90313173A EP 90313173 A EP90313173 A EP 90313173A EP 0431905 A1 EP0431905 A1 EP 0431905A1
Authority
EP
European Patent Office
Prior art keywords
phage
proteins
ultrafiltration
phage dna
membrane filter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP90313173A
Other languages
German (de)
French (fr)
Other versions
EP0431905B1 (en
Inventor
Kazuo Ogawa
Akihiro Nishi
Kenji Koyama
Takanori Matsuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tosoh Corp
RIKEN Institute of Physical and Chemical Research
Original Assignee
Tosoh Corp
RIKEN Institute of Physical and Chemical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tosoh Corp, RIKEN Institute of Physical and Chemical Research filed Critical Tosoh Corp
Publication of EP0431905A1 publication Critical patent/EP0431905A1/en
Application granted granted Critical
Publication of EP0431905B1 publication Critical patent/EP0431905B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes

Definitions

  • the present invention relates to a method for purifying phage DNA.
  • the method of the present invention may be used in the field of genetic engineering.
  • nucleic acids are widely purified from various cells, viruses and phages.
  • Purification of phage DNAs is generally carried out in this technique.
  • the widely adopted conventional method for purifying phage DNAs from the culture medium comprises the steps of removing E . coli cells from the culture medium by centrifugation, precipitating the phage by treatment with polyethyleneglycol, removing proteins by phenol extraction and concentrating DNA by ethanol precipitation.
  • the object of the present invention is to provide a process of purifying phage DNAs by which phage DNAs may be purified to high purity without centrifugation steps and without using reagents toxic to human.
  • phage DNAs may be purified to high purity by removing E . coli cells by filtration through a membrane filter, decomposing and denaturing the phage proteins, and then removing the proteins by ultrafiltration, to complete the present invention.
  • the present invention provides a method for purifying phage DNAs comprising, in the order mentioned, the steps of filtering a mixture containing microorganism cells and phage through a membrane filter to obtain a filtrate, so as to remove said microorganism cells; decomposing and denaturing phage proteins in said filtrate; and subjecting the resultant to ultrafiltration so as to remove impurities.
  • phage DNAs may be purified to high purity with high yield from a culture medium without conducting a centrifugation step.
  • the method since the centrifugation steps is not necessary, the method may be automatized. Further, with the method of the present invention, toxic reagents are not necessary and the time required for the purification is shortened.
  • the drawing shows an agarose gel electrophoresis pattern of a phage DNA purified by the method of the present invention together with an electrophoresis pattern of the phage DNA purified by the conventional method and an electrophoresis pattern of a commercially available phage DNA.
  • a mixture containing microorganism cells and phage is treated.
  • Representative example of such a mixture is a culture medium of a microorganism which is infected with a virus.
  • the culture medium may be treated as it is by the method of the present invention.
  • a culture medium containing M13 phage and E . coli in 2 x TY medium or the like may be treated by the method of the present invention.
  • the above-described mixture is filtered through a membrane filter so as to remove microorganism cells.
  • the pore size of the membrane filter used here may preferably be 0.45 - 0.22 ⁇ m.
  • the material constituting the membrane filter is not at all restricted.
  • the phage proteins in the filtrate is decomposed and denatured.
  • the decomposition and denaturation of the proteins may be carried out by treating the filtrate with a proteolytic enzyme such as Proteinase K.
  • the concentration of the proteolytic enzyme may be appropriately selected.
  • the concentration of the proteolytic enzyme may usually be 0.001 - 0.5 mg/ml.
  • the decomposition and denaturation of the phage proteins may be carried out by treatment with an organic solvent, a surfactant or an alkali or by heat treatment or the like. More particularly, the step of decomposing and denaturing the proteins may be carried out by treating the protein with an organic solvent such as 30 - 100% methanol or ethanol.
  • the separation of DNA and proteins may be attained by using a reagent which does not have a decomposing ability as strong as proteolytic enzymes or organic solvents, when a comparatively simple phage is to be treated.
  • the decomposition and denaturation of proteins may be attained by treatment with a surfactant.
  • the surfactant include anion surfactants such as sodium lauryl sulfate (SDS).
  • SDS sodium lauryl sulfate
  • the concentration thereof may preferably be 0.01 - 1% by weight.
  • heat may be utilized for the protein-nucleic acid separation.
  • the heat treatment may preferably be carried out at a temperature of 80 - 100°C for 5 - 20 minutes.
  • the decomposition and denaturation of the proteins may also be carried out by alkali treatment.
  • Preferred examples of the alkali include aqueous solution of alkaline metal hydroxides with a concentration of 0.1 - 1N.
  • proteins can be removed from the phage DNA.
  • the resulting solution is then ultrafiltered.
  • the ultrafiltration membrane used herein preferably has a fractionation molecular weight of 20,000 to 1,000,000. If the molecular weight to be fractionated is smaller than this range, the efficiency of the removal of proteins is reduced. On the other hand, if the molecular weight is larger than this range, DNA may pass through the ultrafilter.
  • the ultrafilter may be made of any material. For example, commercially available ultrafilters made of polysulfone may be employed. After the ultrafiltration, by washing the ultrafilter with an appropriate solution such as a buffer solution, the phage DNA may be recovered as a solution. To promote the yield of the phage DNA, it is preferred to wash the ultrafilter by passing the solution through the ultrafilter. The solution to be used for washing the ultrafilter is not restricted.
  • TE-buffer Tris-HCl buffer containing EDTA
  • TE-buffer Tris-HCl buffer containing EDTA
  • the second step may be carried out immediately after the first step as described above.
  • the obtained filtrate may be subjected to ultrafiltration to remove low molecular components, thereby purifying the phage.
  • the ultrafiltration may be carried out in the same manner as in the third step just described above.
  • the treatment for decomposing and denaturing the proteins in the second step may be carried out on the ultrafilter, and the ultrafiltration in the third step may be carried out on the same ultrafilter.
  • E . coli JM109 was inoculated to 2 ⁇ TY medium, and then M13 phage was infected thereto. The medium was incubated at 37°C for 4 hours.
  • the resulting culture medium was filtered through a membrane filter having a pore size of 0.45 ⁇ m under a pressure with nitrogen gas.
  • the obtained filtrate was subjected to ultrafiltration through a ultrafilter having a fractionation molecular weight of 300,000 to remove low molecular weight components in the culture medium.
  • a ultrafilter having a fractionation molecular weight of 300,000 to remove low molecular weight components in the culture medium.
  • 5 ⁇ g/ ⁇ l solution of proteinase K was placed on the ultrafilter, and the reaction was allowed to occur for 10 minutes.
  • the enzyme solution was removed under pressure, and the ultrafilter was washed with TE buffer by passing through the buffer under pressure through the ultrafilter. Two hundred microliters of TE buffer was placed on the ultrafilter and the ultrafilter was shaken. Thereafter, the TE buffer was recovered by using a pipette.
  • phage DNA was subjected to agarose gel electrophoresis according to a conventional method.
  • commercially available M13 phage DNA and the M13 phage DNA purified by the conventional purification method comprising polyethylene glycol precipitation and phenol extraction were also subjected to agarose gel electrophoresis.
  • lane 1 shows an electrophoresis pattern of molecular weight markers consisting of Hin dIII digest of ⁇ phage
  • lane 2 shows an electrophoresis pattern of commercially available M13 phage single-stranded DNA
  • lane 3 shows an electrophoresis pattern of M13 phage DNA purified by the conventional polyethylene glycol precipitation and phenol extraction
  • lane 4 shows an electrophoresis pattern of M13 phage DNA purified by the method of the present invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Disclosed is a method for purifying phage DNA which can be carried out without centrifugation steps and without use of toxic reagents. In the method of the invention, a mixture containing microorganism cells and phage is filtered through a membrane filter so as to remove said microorganism cells. Then phage proteins are decomposed and denatured. Thereafter, the resultant is subjected to ultrafiltration so as to remove impurities.

Description

    BACKGROUND OF THE INVENTION I. Field of the Invention
  • The present invention relates to a method for purifying phage DNA. The method of the present invention may be used in the field of genetic engineering.
  • II. Description of the Related Art
  • Recently, with the progress of the genetic engineering techniques, nucleic acids are widely purified from various cells, viruses and phages. For determining base sequences of DNAs carrying genetic information, it is an important technique to replicate single-stranded DNAs by culturing M13 phage with E. coli. Purification of phage DNAs is generally carried out in this technique. The widely adopted conventional method for purifying phage DNAs from the culture medium comprises the steps of removing E. coli cells from the culture medium by centrifugation, precipitating the phage by treatment with polyethyleneglycol, removing proteins by phenol extraction and concentrating DNA by ethanol precipitation.
  • However, with this conventional method, reagents which are toxic to human, such as phenol and chloroform must be used. Further, since centrifugation is necessary in each step, it is difficult to automatize the method. For automatizing the purification, a method which does not require centrifugation is desired.
  • SUMMARY OF THE INVENTION
  • Accordingly, the object of the present invention is to provide a process of purifying phage DNAs by which phage DNAs may be purified to high purity without centrifugation steps and without using reagents toxic to human.
  • The present inventors intensively studied to find that phage DNAs may be purified to high purity by removing E. coli cells by filtration through a membrane filter, decomposing and denaturing the phage proteins, and then removing the proteins by ultrafiltration, to complete the present invention.
  • That is, the present invention provides a method for purifying phage DNAs comprising, in the order mentioned, the steps of filtering a mixture containing microorganism cells and phage through a membrane filter to obtain a filtrate, so as to remove said microorganism cells; decomposing and denaturing phage proteins in said filtrate; and subjecting the resultant to ultrafiltration so as to remove impurities.
  • By the method of the present invention, phage DNAs may be purified to high purity with high yield from a culture medium without conducting a centrifugation step. According to the method of the present invention, since the centrifugation steps is not necessary, the method may be automatized. Further, with the method of the present invention, toxic reagents are not necessary and the time required for the purification is shortened.
  • BRIEF DESCRIPTION OF THE DRAWING
  • The drawing shows an agarose gel electrophoresis pattern of a phage DNA purified by the method of the present invention together with an electrophoresis pattern of the phage DNA purified by the conventional method and an electrophoresis pattern of a commercially available phage DNA.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • In the method of the present invention, a mixture containing microorganism cells and phage is treated. Representative example of such a mixture is a culture medium of a microorganism which is infected with a virus. The culture medium may be treated as it is by the method of the present invention. For example, a culture medium containing M13 phage and E. coli in 2 x TY medium or the like may be treated by the method of the present invention.
  • In the first step of the method of the present invention, the above-described mixture is filtered through a membrane filter so as to remove microorganism cells. The pore size of the membrane filter used here may preferably be 0.45 - 0.22 µm. The material constituting the membrane filter is not at all restricted.
  • In the second step, the phage proteins in the filtrate is decomposed and denatured. The decomposition and denaturation of the proteins may be carried out by treating the filtrate with a proteolytic enzyme such as Proteinase K. In this case, the concentration of the proteolytic enzyme may be appropriately selected. When a culture medium containing M13 phage and E. coli is treated, the concentration of the proteolytic enzyme may usually be 0.001 - 0.5 mg/ml. As described later, it is preferred to subject the filtrate to ultrafiltration before the treatment with a proteolytic enzyme and to add the proteolytic enzyme to the phage remained on the ultrafiltration membrane, although this ultrafiltration step is not required.
  • Other than the treatment with a proteolytic enzyme, the decomposition and denaturation of the phage proteins may be carried out by treatment with an organic solvent, a surfactant or an alkali or by heat treatment or the like. More particularly, the step of decomposing and denaturing the proteins may be carried out by treating the protein with an organic solvent such as 30 - 100% methanol or ethanol. The separation of DNA and proteins may be attained by using a reagent which does not have a decomposing ability as strong as proteolytic enzymes or organic solvents, when a comparatively simple phage is to be treated. For example, the decomposition and denaturation of proteins may be attained by treatment with a surfactant. Preferred examples of the surfactant include anion surfactants such as sodium lauryl sulfate (SDS). In case of using SDS, the concentration thereof may preferably be 0.01 - 1% by weight. Since proteins are weak to heat and nucleic acids such as DNAs are relatively strong to heat, heat may be utilized for the protein-nucleic acid separation. In this case, the heat treatment may preferably be carried out at a temperature of 80 - 100°C for 5 - 20 minutes. The decomposition and denaturation of the proteins may also be carried out by alkali treatment. Preferred examples of the alkali include aqueous solution of alkaline metal hydroxides with a concentration of 0.1 - 1N.
  • The above-mentioned treatments may be carried out individually or in combination. By this step, proteins can be removed from the phage DNA.
  • The resulting solution is then ultrafiltered. The ultrafiltration membrane used herein preferably has a fractionation molecular weight of 20,000 to 1,000,000. If the molecular weight to be fractionated is smaller than this range, the efficiency of the removal of proteins is reduced. On the other hand, if the molecular weight is larger than this range, DNA may pass through the ultrafilter. The ultrafilter may be made of any material. For example, commercially available ultrafilters made of polysulfone may be employed. After the ultrafiltration, by washing the ultrafilter with an appropriate solution such as a buffer solution, the phage DNA may be recovered as a solution. To promote the yield of the phage DNA, it is preferred to wash the ultrafilter by passing the solution through the ultrafilter. The solution to be used for washing the ultrafilter is not restricted. Widely used buffer solutions such as TE-buffer (Tris-HCl buffer containing EDTA) may be employed as the solution for washing the ultrafilter. By this ultrafiltration step, the proteins and other impurities are removed from the solution obtained in the second step, so that phage DNA is purified.
  • The second step may be carried out immediately after the first step as described above. However, after the first step, the obtained filtrate may be subjected to ultrafiltration to remove low molecular components, thereby purifying the phage. In this case, the ultrafiltration may be carried out in the same manner as in the third step just described above. Further, if this ultrafiltration step is employed, the treatment for decomposing and denaturing the proteins in the second step may be carried out on the ultrafilter, and the ultrafiltration in the third step may be carried out on the same ultrafilter.
  • Example
  • The invention will now be described by way of an example thereof. The example is presented for illustration purpose only and should not be interpreted in any restrictive way.
  • E. coli JM109 was inoculated to 2 × TY medium, and then M13 phage was infected thereto. The medium was incubated at 37°C for 4 hours.
  • The resulting culture medium was filtered through a membrane filter having a pore size of 0.45 µm under a pressure with nitrogen gas.
  • The obtained filtrate was subjected to ultrafiltration through a ultrafilter having a fractionation molecular weight of 300,000 to remove low molecular weight components in the culture medium. To decompose the proteins of the phage, 5 µg/µl solution of proteinase K was placed on the ultrafilter, and the reaction was allowed to occur for 10 minutes.
  • The enzyme solution was removed under pressure, and the ultrafilter was washed with TE buffer by passing through the buffer under pressure through the ultrafilter. Two hundred microliters of TE buffer was placed on the ultrafilter and the ultrafilter was shaken. Thereafter, the TE buffer was recovered by using a pipette.
  • By this procedure, 2.5 µg of phage DNA was recovered from 2 ml of the culture medium.
  • The thus obtained phage DNA was subjected to agarose gel electrophoresis according to a conventional method. As controls, commercially available M13 phage DNA and the M13 phage DNA purified by the conventional purification method comprising polyethylene glycol precipitation and phenol extraction were also subjected to agarose gel electrophoresis.
  • The results are shown in the drawing. In the drawing, lane 1 shows an electrophoresis pattern of molecular weight markers consisting of HindIII digest of λ phage, lane 2 shows an electrophoresis pattern of commercially available M13 phage single-stranded DNA, lane 3 shows an electrophoresis pattern of M13 phage DNA purified by the conventional polyethylene glycol precipitation and phenol extraction, and lane 4 shows an electrophoresis pattern of M13 phage DNA purified by the method of the present invention.
  • As is apparent from the drawing, it was confirmed that the phage DNA was purified to high purity by the method of the present invention.
  • Although the present invention was described by way of preferred embodiment thereof, it is apparent for those skilled in the art that various modifications may be made without departing from the spirit and scope of the present invention.

Claims (5)

  1. A method for purifying phage DNA comprising, in the order mentioned, the steps of:
    filtering a mixture containing microorganism cells and phage through a membrane filter to obtain a filtrate, so as to remove the said microorganism cells;
    decomposing and denaturing phage proteins in the said filtrate; and
    subjecting the resultant to ultrafiltration so as to remove impurities.
  2. A method as claimed in Claim 1, characterised in that the pore size of the said membrane filter is 0.45 µm to 0.22 µm.
  3. A method as claimed in Claim 1 or Claim 2 characterised in that the molecular weight to be fractionated by the said ultrafiltration is in the range 20,000 to 1,000,000.
  4. A method as claimed in Claim 1, 2 or 3 characterised in that the step of decomposing and denaturing phage proteins is carried out by treating the said phage proteins with a proteolytic enzyme.
  5. A method as claimed in Claim 1, 2, 3 or 4 characterised in that it further comprises the step of ultrafiltration of the said filtrate obtained in the first step from the membrane filter before the said step of decomposing and denaturing the phage proteins.
EP19900313173 1989-12-06 1990-12-05 Method for purifying phage DNA Expired - Lifetime EP0431905B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1317114A JP2978518B2 (en) 1989-12-06 1989-12-06 Method for purifying phage DNA
JP317114/89 1989-12-06

Publications (2)

Publication Number Publication Date
EP0431905A1 true EP0431905A1 (en) 1991-06-12
EP0431905B1 EP0431905B1 (en) 1994-05-11

Family

ID=18084596

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900313173 Expired - Lifetime EP0431905B1 (en) 1989-12-06 1990-12-05 Method for purifying phage DNA

Country Status (3)

Country Link
EP (1) EP0431905B1 (en)
JP (1) JP2978518B2 (en)
DE (1) DE69008825T2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517515A2 (en) * 1991-06-04 1992-12-09 Tosoh Corporation Method of purifying DNA
WO1993001312A1 (en) * 1991-07-09 1993-01-21 Bertin & Cie Cartridge, device and method for preparing purified nucleic acids from a cell sample
WO1993011218A1 (en) * 1991-12-02 1993-06-10 Qiagen Gmbh Method and device for the isolation of cell components, such as nucleic acids, from natural sources
FR2712511A1 (en) * 1993-11-16 1995-05-24 Bertin & Cie Cartridge for the preparation of purified nucleic acids.
US6011148A (en) * 1996-08-01 2000-01-04 Megabios Corporation Methods for purifying nucleic acids
WO2000005358A1 (en) * 1998-07-23 2000-02-03 Valentis, Inc. Methods for purifying nucleic acids
WO2000066723A1 (en) * 1999-05-04 2000-11-09 Millipore Corporation Method of ultrafiltration
US6498240B1 (en) 1999-09-17 2002-12-24 Millipore Corporation Method for sequencing reaction cleanup by constant pressure diffential ultrafiltration
US7026468B2 (en) 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7314746B2 (en) 2002-09-13 2008-01-01 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
US8008475B1 (en) * 1997-10-23 2011-08-30 Qiagen Gmbh Method for isolating and purifying nucleic acids on surfaces
CN115354041A (en) * 2022-10-19 2022-11-18 北京君全智药生物科技有限公司 Preparation method of M13 phage single-stranded DNA

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008055606A1 (en) 2008-11-03 2010-05-06 Bayer Technology Services Gmbh A method for the high-throughput preparation of sequencing-competent DNA from individual plaques of peptides presenting phages

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240191A2 (en) * 1986-03-13 1987-10-07 Seiko Instruments Inc. Method of isolating DNA contained in a virus or cell
WO1989001035A1 (en) * 1987-07-23 1989-02-09 Europäisches Laboratorium Für Molekularbiologie (E Process and device for purification of m-13 phage dna
EP0376080A1 (en) * 1988-12-22 1990-07-04 Talent SRL Method for the extraction and purification of DNA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240191A2 (en) * 1986-03-13 1987-10-07 Seiko Instruments Inc. Method of isolating DNA contained in a virus or cell
WO1989001035A1 (en) * 1987-07-23 1989-02-09 Europäisches Laboratorium Für Molekularbiologie (E Process and device for purification of m-13 phage dna
EP0376080A1 (en) * 1988-12-22 1990-07-04 Talent SRL Method for the extraction and purification of DNA

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517515A3 (en) * 1991-06-04 1993-06-16 Tosoh Corporation Method of purifying dna
EP0517515A2 (en) * 1991-06-04 1992-12-09 Tosoh Corporation Method of purifying DNA
WO1993001312A1 (en) * 1991-07-09 1993-01-21 Bertin & Cie Cartridge, device and method for preparing purified nucleic acids from a cell sample
US5352609A (en) * 1991-07-09 1994-10-04 Bertin & Cie Cartridge, apparatus, and method for preparing purified nucleic acids from a cell sample
US6277648B1 (en) 1991-12-02 2001-08-21 Qiagen Gmbh Process and a device for the isolation of cell components such as nucleic acids from natural sources
WO1993011218A1 (en) * 1991-12-02 1993-06-10 Qiagen Gmbh Method and device for the isolation of cell components, such as nucleic acids, from natural sources
US6609618B2 (en) 1991-12-02 2003-08-26 Qiagen Gmbh Device for the isolation of cell components such as nucleic acids from natural sources
FR2712511A1 (en) * 1993-11-16 1995-05-24 Bertin & Cie Cartridge for the preparation of purified nucleic acids.
WO1995014086A1 (en) * 1993-11-16 1995-05-26 Bertin & Cie Cartridge for preparing purified nucleic acids
US5789243A (en) * 1993-11-16 1998-08-04 Bertin & Cie Cartridge for preparing purified nucleic acids
US7026468B2 (en) 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US8236495B2 (en) 1996-07-19 2012-08-07 Samuel Nochumson Process and equipment for plasmid purification
US6011148A (en) * 1996-08-01 2000-01-04 Megabios Corporation Methods for purifying nucleic acids
US7807822B2 (en) 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
US8008475B1 (en) * 1997-10-23 2011-08-30 Qiagen Gmbh Method for isolating and purifying nucleic acids on surfaces
WO2000005358A1 (en) * 1998-07-23 2000-02-03 Valentis, Inc. Methods for purifying nucleic acids
WO2000066723A1 (en) * 1999-05-04 2000-11-09 Millipore Corporation Method of ultrafiltration
US6498240B1 (en) 1999-09-17 2002-12-24 Millipore Corporation Method for sequencing reaction cleanup by constant pressure diffential ultrafiltration
US6645722B2 (en) 1999-09-17 2003-11-11 Millipore Corporation Method for sequencing reaction cleanup by constant differential pressure ultrafiltration
US7314746B2 (en) 2002-09-13 2008-01-01 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
US7771945B2 (en) 2002-09-13 2010-08-10 Au-Yeung Kwok-Leung Jacky Apparatus and method for preparative scale purification of nucleic acids
CN115354041A (en) * 2022-10-19 2022-11-18 北京君全智药生物科技有限公司 Preparation method of M13 phage single-stranded DNA

Also Published As

Publication number Publication date
JPH03180182A (en) 1991-08-06
EP0431905B1 (en) 1994-05-11
DE69008825D1 (en) 1994-06-16
DE69008825T2 (en) 1994-08-25
JP2978518B2 (en) 1999-11-15

Similar Documents

Publication Publication Date Title
EP0431905B1 (en) Method for purifying phage DNA
US6969603B2 (en) Method for isolating DNA
EP0442026B1 (en) Method to extract and purify human genomic DNA
US5010183A (en) Process for purifying DNA and RNA using cationic detergents
US4446237A (en) Method for detection of a suspect viral deoxyribonucleic acid in an acellular biological fluid
EP0554034B1 (en) Shelf-stable product and process for isolating RNA, DNA and proteins
WO1997010331A1 (en) Method for purifying nucleic acids from homogeneous mixtures
US4833239A (en) Method for the isolation and purification of DNA molecules
DE60009912D1 (en) METHOD FOR RNASE- AND ORGANIC SOLVENT-FREE PURIFICATION OF PLASMID DNA BY TANGENTIAL FLOW FILTRATION
JPH04360686A (en) Purification of dna
WO1994026287A1 (en) Purification of plasma proteins
CA1328839C (en) Composition for isolating and purifying nucleic acid and improved method using same
WO1987007645A1 (en) A method of sequencing nucleic acids
EP0240191A2 (en) Method of isolating DNA contained in a virus or cell
EP0370163A1 (en) Enzymatic purification process
AU782588B2 (en) Method for purifying nucleic acids from feces
JPH0666B2 (en) Method for isolating and purifying DNA
CA2326374C (en) Process for the recovery and purification of a recombinant protein from a cell
Sims et al. Single-stranded phage replication: positive-and negative-strand DNA synthesis
JP3588370B2 (en) Kit for extracting viral nucleic acid from blood component and method for extracting viral nucleic acid using the reagent
JP3108463B2 (en) DNA purification method
WO1994012657A1 (en) Direct-phenol pcr, rt and rt-pcr methods
EP0708828B1 (en) Obtaining nucleic acids
JPH08187086A (en) Purification of viral gene
JPH04349892A (en) Method for isolating nucleic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB LI SE

17P Request for examination filed

Effective date: 19911203

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RIKEN INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH

Owner name: TOSOH CORPORATION

17Q First examination report despatched

Effective date: 19930803

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE FR GB LI SE

REF Corresponds to:

Ref document number: 69008825

Country of ref document: DE

Date of ref document: 19940616

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19941205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19941206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19941231

Ref country code: CH

Effective date: 19941231

EAL Se: european patent in force in sweden

Ref document number: 90313173.8

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19941205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19950831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19950901

EUG Se: european patent has lapsed

Ref document number: 90313173.8

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST